PITTSBURGH, PA / May 20, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer, Dr. Douglas W. Losordo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
In his latest blog post, Dr. Losordo shares his perspective on randomized clinical trials. He emphasizes the importance of interpreting data in clinical studies and how it can often be construed quite variably. Read the full blog post from Dr. Losordo on TheChairmansBlog.com (http://www.thechairmansblog.com/neostem/douglas-losordo/interpreting-data-correctly/).
About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com
SOURCE: The Chairmans Blog